{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:09:25Z","timestamp":1780459765720,"version":"3.54.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.intimp.2022.109004","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T12:15:22Z","timestamp":1656677722000},"page":"109004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Comparison on the effect of seven drugs to prevent relapses of neuromyelitis optica spectrum disorders: A modeling analysis of literature aggregate data"],"prefix":"10.1016","volume":"110","author":[{"given":"Jieren","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiesen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichao","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2022.109004_b0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-16625-7","article-title":"Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica","volume":"11","author":"Agasing","year":"2020","journal-title":"Nat Commun."},{"issue":"5","key":"10.1016\/j.intimp.2022.109004_b0010","doi-asserted-by":"crossref","first-page":"e1034","DOI":"10.1212\/NXI.0000000000001034","article-title":"Molecular Level Characterization of Circulating Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder","volume":"8","author":"Li","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"2","key":"10.1016\/j.intimp.2022.109004_b0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"issue":"5","key":"10.1016\/j.intimp.2022.109004_b0020","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"8","key":"10.1016\/j.intimp.2022.109004_b0025","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1468-1331.2010.03066.x","article-title":"EFNS guidelines on diagnosis and management of neuromyelitis optica","volume":"17","author":"Sellner","year":"2010","journal-title":"Eur J Neurol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109004_b0030","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of Neuromyelitis Optica in the United States: A Multicenter Analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch Neurol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109004_b0035","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1212\/WNL.0000000000007746","article-title":"Epidemiology of NMOSD in Sweden from 1987 to 2013: A nationwide population-based study","volume":"93","author":"Jonsson","year":"2019","journal-title":"Neurology."},{"key":"10.1016\/j.intimp.2022.109004_b0040","doi-asserted-by":"crossref","first-page":"103080","DOI":"10.1016\/j.msard.2021.103080","article-title":"Asian and African\/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence","volume":"53","author":"Soares-dos-Reis","year":"2021","journal-title":"Mult Scler Relat Disord."},{"issue":"4","key":"10.1016\/j.intimp.2022.109004_b0045","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/ene.14654","article-title":"Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: A comparative study in Chinese Han patients","volume":"28","author":"ZhangBao","year":"2021","journal-title":"Eur J Neurol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109004_b0050","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ana.20770","article-title":"Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis","volume":"59","author":"Weinshenker","year":"2006","journal-title":"Ann Neurol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109004_b0055","doi-asserted-by":"crossref","first-page":"e947","DOI":"10.1212\/NXI.0000000000000947","article-title":"Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies","volume":"8","author":"Kim","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"1","key":"10.1016\/j.intimp.2022.109004_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol."},{"key":"10.1016\/j.intimp.2022.109004_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol."},{"issue":"4","key":"10.1016\/j.intimp.2022.109004_b0070","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/bcp.12533","article-title":"Quantitative efficacy of soy isoflavones on menopausal hot flashes","volume":"79","author":"Li","year":"2015","journal-title":"Br J Clin Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2022.109004_b0075","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Neuromyelitis optica. Nat Rev Dis Primers."},{"key":"10.1016\/j.intimp.2022.109004_b0080","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/ITT.S287652","article-title":"Drug Treatment of Neuromyelitis Optica Spectrum Disorders: Out with the Old, in with the New?","volume":"10","author":"Held","year":"2021","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.intimp.2022.109004_b0085","article-title":"Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder","author":"Liu","year":"2021","journal-title":"J Formos Med Assoc."},{"key":"10.1016\/j.intimp.2022.109004_b0090","doi-asserted-by":"crossref","first-page":"102750","DOI":"10.1016\/j.msard.2021.102750","article-title":"Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy","volume":"49","author":"Takai","year":"2021","journal-title":"Mult Scler Relat Disord."},{"issue":"8","key":"10.1016\/j.intimp.2022.109004_b0095","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","article-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult Scler."},{"key":"10.1016\/j.intimp.2022.109004_b0100","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jclinepi.2020.06.015","article-title":"The revised Cochrane risk of bias tool for randomized trials (RoB 2) showed low interrater reliability and challenges in its application","volume":"126","author":"Minozzi","year":"2020","journal-title":"J Clin Epidemiol."},{"key":"10.1016\/j.intimp.2022.109004_b0105","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.intimp.2022.109004_b0110","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/cpt.1783","article-title":"Pharmacokinetics and Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis","volume":"107","author":"Ding","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2022.109004_b0115","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1023\/A:1011970125687","article-title":"Automated covariate model building within NONMEM","volume":"15","author":"Jonsson","year":"1998","journal-title":"Pharm Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.109004_b0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","article-title":"Diagnosing model diagnostics","volume":"82","author":"Karlsson","year":"2007","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.intimp.2022.109004_b0125","unstructured":"Holford N. The Visual Predictive Check \u2013 Superiority to Standard Diagnostic (Rorschach) Plots. PAGE 14 (2005) Abstr 738. [www.page-meeting.org\/?abstract=738]."},{"key":"10.1016\/j.intimp.2022.109004_b0130","series-title":"An introduction to the bootstrap","author":"Efron","year":"1994"},{"key":"10.1016\/j.intimp.2022.109004_b0135","doi-asserted-by":"crossref","first-page":"102685","DOI":"10.1016\/j.msard.2020.102685","article-title":"Frequency of comorbidities in Neuromyelitis Optica spectrum disorder","volume":"48","author":"Barzegar","year":"2021","journal-title":"Mult Scler Relat Disord."},{"issue":"3","key":"10.1016\/j.intimp.2022.109004_b0140","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000705","article-title":"Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders: A prospective study","volume":"7","author":"Li","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"7","key":"10.1016\/j.intimp.2022.109004_b0145","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med."},{"issue":"10206","key":"10.1016\/j.intimp.2022.109004_b0150","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.intimp.2022.109004_b0155","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109004_b0160","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109004_b0165","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/13524585211038291","article-title":"Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension","volume":"28","author":"Pittock","year":"2022","journal-title":"Mult Scler."},{"issue":"3","key":"10.1016\/j.intimp.2022.109004_b0170","doi-asserted-by":"crossref","first-page":"e978","DOI":"10.1212\/NXI.0000000000000978","article-title":"Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder","volume":"8","author":"Marignier","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"8","key":"10.1016\/j.intimp.2022.109004_b0175","first-page":"3475","article-title":"Efficacy and safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD): Results from open-label extension periods of SAkuraSky and SAkuraStar","volume":"62","author":"Haskova","year":"2021","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.intimp.2022.109004_b0180","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.msard.2019.08.009","article-title":"Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis","volume":"35","author":"Huang","year":"2019","journal-title":"Mult Scler Relat Disord."},{"issue":"1","key":"10.1016\/j.intimp.2022.109004_b0185","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40120-021-00295-8","article-title":"Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder","volume":"11","author":"Wingerchuk","year":"2022","journal-title":"Neurol Ther."},{"key":"10.1016\/j.intimp.2022.109004_b0190","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.604445","article-title":"Different Targets of Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders: A Meta-Analysis Evidenced From Randomized Controlled Trials","volume":"11","author":"Xue","year":"2020","journal-title":"Front Neurol."},{"key":"10.1016\/j.intimp.2022.109004_b0195","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jns.2016.09.035","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study","volume":"370","author":"Xu","year":"2016","journal-title":"J Neurol Sci."},{"key":"10.1016\/j.intimp.2022.109004_b0200","doi-asserted-by":"crossref","first-page":"102484","DOI":"10.1016\/j.msard.2020.102484","article-title":"Efficacy and safety of azathioprine for neuromyelitis optica spectrum disorders: A meta-analysis of real-world studies","volume":"46","author":"Luo","year":"2020","journal-title":"Mult Scler Relat Disord."},{"issue":"1","key":"10.1016\/j.intimp.2022.109004_b0205","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-73882-8","article-title":"Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"10","author":"Songwisit","year":"2020","journal-title":"Sci Rep."},{"key":"10.1016\/j.intimp.2022.109004_b0210","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.737564","article-title":"Physical, Emotional, Medical, and Socioeconomic Status of Patients With NMOSD: A Cross-Sectional Survey of 123 Cases From a Single Center in North China","volume":"12","author":"Jia","year":"2021","journal-title":"Front Neurol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109004_b0215","doi-asserted-by":"crossref","first-page":"e0229028","DOI":"10.1371\/journal.pone.0229028","article-title":"Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis","volume":"15","author":"Aungsumart","year":"2020","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.intimp.2022.109004_b0220","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00415-019-09649-7","article-title":"Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study","volume":"267","author":"Shi","year":"2020","journal-title":"J Neurol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109004_b0225","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109004_b0230","doi-asserted-by":"crossref","first-page":"e1027","DOI":"10.1212\/NXI.0000000000001027","article-title":"Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases","volume":"8","author":"Schanda","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.intimp.2022.109004_b0235","doi-asserted-by":"crossref","first-page":"102251","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Mult Scler Relat Disord."},{"issue":"3","key":"10.1016\/j.intimp.2022.109004_b0240","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3988\/jcn.2020.16.3.355","article-title":"Monoclonal Antibody Therapies for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder","volume":"16","author":"Kim","year":"2020","journal-title":"J Clin Neurol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692200488X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692200488X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:56:20Z","timestamp":1761587780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692200488X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":48,"alternative-id":["S156757692200488X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109004","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison on the effect of seven drugs to prevent relapses of neuromyelitis optica spectrum disorders: A modeling analysis of literature aggregate data","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109004"}}